The global market for Human Papillomaviruses (HPV) therapeutic vaccines is examined in a detailed market research report by Transparency Market Research. The report, titled “HPV Therapeutic Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” gives a thorough overview of the present state of the market and its key elements. Based on detailed qualitative and quantitative data gathered for the past and present years, industry expert opinions, and industry-best analytical approaches, a forecast concerning the way the market is projected to expand from 2013 to 2019 is also included.
The vast rise in the prevalence of cervical cancers, nearly all cases of which are caused by HPV, and other varieties of HPV infections are the chief drivers of the global HPV therapeutic vaccines market. Rising numbers of cases of oropharyngeal cancers, vaginal cancers, penile cancers, and vulvar cancers are also boosting the growth prospects of the global HPV therapeutic vaccines market.
Download free exclusive Brochure of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1936
Presently, two HPV therapeutics vaccines approved by the U.S. FDA, namely Gardasil by Merck & Co., Inc. and Cervarix by GSK Pharmaceuticals Ltd., are among the most popular products in the global HPV therapeutic vaccines market. The market, being in a nascent stage of development, more such products are expected to hit the market in the near future.
However, owing to the scarcity of therapeutic options in the market presently, the implementation of mass vaccinations for the prevention of cervical cancers is expected to take a couple of decades. The two therapeutic vaccines mentioned above have not proven to provide complete protection against complex infections caused by many HPVs. Thus, there is immense scope of development in the global HPV therapeutic vaccines market. The HPV strains targeted by these two vaccines are type 6, 11, 16, and 18.
The global annual incidences of cervical cancer is nearly 0.5 million presently. Additionally, the annual incidence of high-grade cervical intraepithelial neoplasia (CIN), which is commonly referred to as the precancerous condition of cervical cancer, is also nearly 0.5 mn across the globe. In the near future, the incidence rate of HPV related cancers is expected to rise by 40%. Europe and North America are the most promising regional markets for HPV therapeutics vaccines as government bodies across several countries in these regions have invested vast funds in the research and development of HPV vaccines.
The key players operating in the global HPV therapeutics vaccines market are GlaxoSmithKline Pharmaceuticals Ltd. and Merck& Co., Inc. Products developed by many other companies such as Advaxis Inc., Coridon, and Genticel are in pipeline.
For more information:
Last updated on: 27/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.